Neuroimaging System Receives FDA Clearance
Compumedics secures approval for neuroimaging system for epilepsy and pre-surgical brain function mapping.
Medical device company Compumedics has received U.S. Food and Drug Administration approval for its brain activity-mapping neuroimaging technology, Orion LifeSpan™ Magnetoencephalography (MEG).
The 510(k) clearance greenlights the MEG single Dewar system that maps brain activity by recording magnetic fields that are generated by the brain’s natural electrical currents. Powered by the CURRY™ neuroimaging platform, Orion LifeSpan offers a dual-helmet system, enabling recordings for both adult and pediatric patients.
In addition, according to company information, the system is vibration-free and vacuum-cooled with zero-loss helium recycling. It also offers real-time video archiving and full cloud integration.
Based on a press statement, this technology, which sells for between $3-4 million, can primarily be applied in the clinical setting for epilepsy and pre-surgical brain function mapping. The Barrow Neurological Institute in Arizona has completed the first installation and first-phase commissioning of the system.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
